Uncategorized

July 15th, 2011

The Evolution of Social Media: EVO 2011 Conference

From Susan Can, Director, Corporate Equity, Johnson & Johnson Global Marketing Group

On the weekend of July 7th, I had the pleasure of attending the EVO conference where Johnson & Johnson was one of the corporate sponsors.   Set in the scenic mountains of Park City, Utah, this was an amazing experience for us. We were able to meet and talk with so many people who are making a difference in the world by harnessing the power of the internet.

While many bloggers at the conference cover topics related to home, family and health, many also cover topics related to using social media for social good: using the power of the internet to champion specific causes to make a difference.  We were there to engage with attendees on this shared topic of interest – using, “Social Media for Social Good.” 

Visitors to the Johnson & Johnson suite were introduced to three varied aspects of what is happening in the world of social media and Johnson & Johnson.  We introduced &you™ (a brand new digital tool for social good – more on that below).  Participants were able to learn about specific causes that Johnson & Johnson supports, as well as given an opportunity to share their story on how they use social media for social good.

Read More

July 11th, 2011

Using Innovation to Meet Health Care Needs in Asia

From Michael del Prado, Company Group Chairman, Medical Devices & Diagnostics, Asia-Pacific.

The other week, I attended the opening of the Johnson & Johnson Medical Companies Innovation Center in Suzhou, China, our first medical devices and diagnostics innovation center in China and our second in Asia.  The opening of this center comes at a very special time for Johnson & Johnson — during our 125th anniversary year — and it continues one of our oldest traditions as a company:  working to meet unmet health care needs. 

The Asia-Pacific region of the world where I live and work is home to almost 60 percent of the world’s population, but many people in these emerging economies lack access to quality health care.   That’s something we want to help change. 

Johnson & Johnson has been doing business in China, India and other Asian countries for a very long time, first selling our products through local distributors and later opening operating companies in Asia, well ahead of many other multinationals.  We’ve had companies in China since 1982, but access to many of our products centered around the main population centers like Shanghai or Beijing.   The Suzhou Innovation Center will allow us to better serve the millions of men, women and children outside of the main population centers in China who are now gaining access to some degree of healthcare coverage. 

Read More

June 30th, 2011

Johnson & Johnson Recognized at the 2011 Dosie Awards

From Ray Jordan, Corporate Vice President, Public Affairs and Corporate Communication, Johnson & Johnson

The 2011 Dosie Awards, which aim to highlight some of the best examples of social media in the healthcare industry, were recently announced and I’m proud to say Johnson & Johnson was named Company of the Year in Social Media based on the awards received by many of our social media properties, including: the Johnson & Johnson Network page on Facebook, the Johnson & Johnson health channel on YouTube, the @JNJStories Twitter feed, Diabetes Handprint, Children with Diabetes and the JNJ BTW corporate blog. I wanted to take a moment to congratulate all our J&J team members who drive, challenge and nurture our presence in the social media space.

We’re always focusing on what we can do better, so it’s pretty humbling to receive such honor and praise for our social media work. It has been an interesting journey for all of us here at Johnson & Johnson as we figure out the best ways to join the online conversation about health care. As we continue to participate in and learn about the social media space, we hope to find new and innovative ways to engage with you and earn your respect every day.

Read More

June 29th, 2011

2011 Dr. Paul Janssen Award for Biomedical Research Honors Biotechnology Pioneer

By Paul Stoffels, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson

Biotechnology has come a long way since the discovery of recombinant DNA almost 40 years ago and the sequencing of the human genome a decade ago.  Today, the term has a broader definition: biomarkers, antibodies, genomics, protemics, RNA, novel scaffolds, peptides, cell therapies, and more, all to help us solve the most important diseases of our time. One example of such an advance is the treatment of angiogenesis, the process of new blood vessel formation that plays a key role in cancer proliferation and a number of other diseases.  These treatments have improved the lives of millions of patients.

Dr. Napoleone Ferrara, Genentech Fellow, has been influential in the development of anti-angiogenesis treatments. Through the identification of a human vascular endothelial cell growth factor (VEGF), he discovered there may be a ways to control the blood supply to particular parts of the body. His innovative work on angiogenesis opened the door to the development of a new class of therapeutics to combat a serious eye disorder and contributed to the development of new oncology therapeutics.

Today Johnson & Johnson honored Dr. Napoleone Ferrara with the 2011 Dr. Paul Janssen Award for Biomedical Research, an award that recognizes passionate and creative scientists like Dr.

Read More

June 28th, 2011

Response to Recent Coverage in the Financial Times

Today’s Financial Times included a story (subscription required) about Johnson & Johnson’s comprehensive approach to preventing and treating disease. The story contained a number of inaccuracies, which Johnson & Johnson addressed in a letter to the Financial Times editors. Here is what we had to say.

Dear Editor of the Financial Times:

Today’s Financial Times included an article about the comprehensive approach of Johnson & Johnson to the prevention and treatment of significant chronic diseases. The story contained a number of inaccuracies.

While Johnson & Johnson believes the breadth of its business interests across consumer, diagnostics and pharmaceuticals business segments is a valuable advantage in its approach to the treatment of a number of chronic conditions, including cancer, the company does not intend to market consumer and regulated products more closely, as reported. In a discussion with the Financial Times, company executives talked about how leaders from the various business segments share insights that improve their understanding of the needs of patients with cancer and other conditions, and, presumably, result in products and services that better meet these needs. They did not, however, state or suggest that the company would market such products together.

Sincerely,

Bill Price
Vice President, Media Relations
Johnson & Johnson

Read More

June 10th, 2011

Advancing the Science at ASCO—Metastatic Prostate Cancer

By Vicki Vakiener, Vice President, Sales & Marketing, Veridex, LLC

Our mission is to care for the world, one patient at a time. As we focus on defeating life-threatening diseases such as cancer, we realize it is our collective knowledge and advanced science that will help us successfully tackle this hefty goal.

Over the past decade, I’ve seen an increase in internal and external collaborations that help us to accelerate the development of novel medicines, diagnostic tools and treatment solutions for patients worldwide. When I can find and apply the best science, I know I’m   delivering on our heritage and serving the patients who rely on our solutions to be healthier, feel better and live longer, everyday.

To that end, I was pleased to see the collaborative efforts of our diagnostic and pharmaceutical teams at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting earlier this week. Together, Ortho Clinical Diagnostics, Inc. and Centocor Ortho Biotech Inc. utilized their expertise to advance the science of metastatic prostate cancer, where there is still an unmet medical need for diagnostic tools and therapies.

While there is still work to be done, I’m pleased at the progress our company has made thus far.

Read More

June 9th, 2011

Ortho Clinical Diagnostics: A Culture of Health

From Nick Valeriani, Company Group Chairman, Ortho Clinical Diagnostics

For more than two years, I’ve been lucky enough to lead a company that I believe exemplifies the Johnson & Johnson ideal of a culture of health. My colleagues and I have been working together to help our employees live our franchise vision: enabling people to be healthier, feel better and live longer. Our vision represents the individual strengths of the three companies within our franchise: Ortho Clinical Diagnostics, Therakos and Veridex. It also brings us together to focus on what matters most – our employees and the people we serve.

Our vision started with our employees’ recognition of the extraordinary value of diagnostics throughout the health care continuum. We work to cultivate an environment where we focus on the benefits of using health information – such as diagnostic tests – to stay healthy and well, and we feel that this should be demonstrated not only in the work that we do, but in our personal lives as well. For example, we talk about the ways in which our products can provide information that’s vital to preserving wellness, as well as managing disease; by offering health and wellness-related educational seminars and programs; by sharing success stories from patients and employees who benefit from our products; and by encouraging employees to evaluate their lifestyles and make small and simple changes for better health.

Read More

June 2nd, 2011

Extending the Benefits of HIV Treatment

From Paul Stoffels, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson

 Extending the benefits of HIV treatment throughout the world is a passion of mine.  As the Worldwide Chairman of Pharmaceuticals for Johnson & Johnson, I’ve been able to see the progress we’ve made in combating this disease over the past few decades. June 5 marks the 30th anniversary of the first report by the U.S. Centers for Disease Control of a disease we would later come to know as HIV.  During those early years of the epidemic, contracting HIV meant a two-year life expectancy. Today, in the western world, HIV has become a chronic condition that can be managed through modern medicine.

Yet, meeting the individual treatment needs of the estimated 33.3 million people living with HIV throughout the world remains an extraordinary challenge.  Our company’s ongoing commitment to addressing this challenge traces all the way back to work in the laboratories of Dr. Paul Janssen.  On Friday, May 20, we reported on a major milestone in these efforts.

As a company, we are also expanding the benefits of our HIV drugs to the developing world.  We have agreements in place with generic manufactures to produce them for sub-Saharan Africa and India

Read More

June 1st, 2011

National Employee Wellness Month

From Dr. Fikry Isaac MD, MPH, Vice President Global Health Services, Johnson & Johnson

As part of my role within the Johnson & Johnson Global Health services organization, I have been privileged with the opportunity to lead our company’s efforts to improve the health and well-being of our employees around the world.  At Johnson & Johnson we understand that an investment in the health of our employees is an investment in the health of our company, which is why I’m glad to announce our proud support for National Employee Wellness Month.  This annual initiative, sponsored by the Partnership to Fight Chronic Disease, Virgin Health Miles and Stop Obesity Alliance, and supported by nearly 100 other companies, helps business leaders share and develop successful strategies for the prevention of chronic disease and maintenance of good health for employees.  Throughout our 125 year history we’ve led the way in our commitment to the health of our employees and we are happy to support an initiative that will help foster a culture of health in other companies.

While a focus on a healthy and productive workforce has long been a hallmark of our company, Johnson & Johnson’s commitment to employee health and wellness began officially with former Chairman James Burke’s pledge to make the employees of Johnson & Johnson’s Family of Companies the healthiest in the world. 

Read More

May 27th, 2011

Yesterday’s Pharmaceutical Business Review

Yesterday, we held a meeting with the investment community to review growth strategies for Johnson & Johnson’s pharmaceuticals business.   It was an in-depth look at how our employees and partners across the world are working to address major unmet needs in a number of areas, and developing an amazing pipeline of new medicines.   Sheri McCoy, vice chairman of the Executive Committee, spoke about meeting needs with science and increasing the capacity to treat patients, saying , “We have the opportunity to make a difference for people around the world.”

Paul Stoffels, M.D., also provided an overview of the strength of the pharmaceuticals pipeline, and Joaquin Duato reviewed the commercial strategies that have enabled our pharmaceuticals businesses to become launch leaders in several categories.  Paul and Joaquin are both Worldwide Chairmen, Pharmaceuticals.  The Company highlighted the expectations of its pharmaceuticals businesses to file 11 new products and more than 30 line extensions in the next five years.  

The R&D leaders took investors on a deeper dive in five therapeutic areas:  neuroscience, cardiovascular and metabolism, immunology, oncology and infectious diseases and vaccines.   They spoke about recent product approvals, the strength of the pharmaceuticals pipeline in these areas, and the geographic reach of the business, both in established markets and in emerging markets.   

Read More